# Prednisone for Heart Failure Patients With Hyperuricemia

Study · id `cardio:ct-nct02129764` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02129764](<https://clinicaltrials.gov/study/NCT02129764>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02129764

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.

## Technical summary

Registry record NCT02129764. Randomized; no masking; primary purpose treatment. Start 2013-12 (actual); primary completion 2018-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 205 participants (enrolled count; ClinicalTrials.gov record NCT02129764, source copy `cardio:ctgov-nct02129764-2018-10-16`, retrieved 2026-10-26)
- Started: 2013-12 (actual) (ClinicalTrials.gov record NCT02129764, source copy `cardio:ctgov-nct02129764-2018-10-16`, retrieved 2026-10-26)
- Primary completion: 2018-02 (actual) (ClinicalTrials.gov record NCT02129764, source copy `cardio:ctgov-nct02129764-2018-10-16`, retrieved 2026-10-26)
- Completion: 2018-08-31 (actual) (ClinicalTrials.gov record NCT02129764, source copy `cardio:ctgov-nct02129764-2018-10-16`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02129764, source copy `cardio:ctgov-nct02129764-2018-10-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02129764-2018-10-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prednisone for Heart Failure Patients With Hyperuricemia
- Acronym: PUSH-PATH-2
- Condition: Heart Failure, Hyperuricemia
- Intervention (Drug): Prednisone
- Intervention (Drug): Allopurinol
- Lead sponsor: Hebei Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: c8efbedaca763aacc564ec7c88e8f8de079114f071b93d719645c1213b407f0e
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
